Short-term treatment with rivastigmine and plasma levels of Aβ peptides in Alzheimer's disease

Folia Neuropathologica

Volumn 43, Issue 4, 2005, Pages 340-344

  Sobow, Tomasz ^a   Kloszewska, Iwona ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

amyloid; Alzheimer's disease; Butyrylcholinesterase; Cholinesterase inhibitors; Plasma; Rivastigmine

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM; SHORT COURSE THERAPY; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; CHOLINESTERASE INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; PHENYLCARBAMATES; TIME FACTORS;

EID: 30944461183     PISSN: 16414640     EISSN: 1509572X     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Banks WA, Robinson SM, Verma S, Morley JE. Efflux of human and mouse amyloid beta proteins 1-40 and 1-42 from brain: impairment in a mouse model of Alzheimer's disease. Neuroscience 2003; 121: 487-492.
2. Basun H, Nilsberth C, Eckman C, Lannfelt L, Younkin S. Plasma levels of Abeta42 and Abeta40 in Alzheimer patients during treatment with the acetylcholinesterase inhibitor tacrine. Dement Geriatr Cogn Disord 2002; 14: 156-160.
3. Borroni B, Colciaghi F, Pastorino L, Pettenati C, Cottini E, Rozzini L, Monastero R, Lenzi GL, Cattabeni F, Di Luca M, Padovani A. Amyloid precursor protein in platelets of patients with Alzheimer disease: effect of acetylcholinesterase inhibitor treatment. Arch Neurol 2001; 58: 442-446.
4. Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, Nagel J, Lane R. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005; 21 (8): 1317-1327.
5. Eskander MF, Nagykery NG, Leung EY, Khelghati B, Geula C. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles. Brain Res 2005; 1060: 144-152.
6. Farlow M, Potkin S, Koumaras B, Veach J, Mirski D. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Arch Neurol 2003; 60: 843-848.
7. Flirski M, Sobow T. Biochemical markers and risk factors of Alzheimer's disease. Curr Alzheimer Res 2005; 2: 47-64.
8. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol 2003; 60: 958-964.
9. Guillozet AL, Smiley JF, Mash DC, Mesulam MM. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 1997; 42: 909-918.
10. Hoglund K, Wiklund O, Vanderstichele H, Eikenberg O, Vanmechelen E, Blennow K. Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. Arch Neurol 2004; 61: 333-337.
11. Kalaria RN. The blood-brain barrier and cerebrovascular pathology in Alzheimer's disease. Ann N Y Acad Sci 1999; 893: 113-125.
12. Kuljis RO, Farlow M, Grossberg G, Geula C, Kaufmann WE, Fuentes P, Maccioni R, Husain M, Mirski D, Rabinowicz A, Khamis I, Edwards K, Ellis J, Farber M, Havlioglu N. Long-term exposure to rivastigmine may reduce senile plaque (sp) density. Program No. 240.10. Washington, DC: Society for Neuroscience, 2003.
13. Lahiri DK, Farlow MR, Sambamurti K. The secretion of amyloid beta-peptides is inhibited in the tacrine-treated numan neuroblastoma cells. Brain Res Mol Brain Res 1998; 62: 131-140.
14. Lahiri DK, Farlow MR, Hintz N, Utsuki T, Greig NH. Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease. Acta Neurol Scand 2000; 176: 60-67.
15. Lane RM, Potkin SG, Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol 2005; 5: 1-24.
16. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992; 258: 304-307.
17. Olsson A, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K. Unaltered plasma levels of beta-amyloid(1-40) and beta-amyloid(1-42) upon stimulation of human platelets. Dement Geriatr Cogn Disord 2003; 16: 93-97.
18. Parnetti L, Amici S, Lanari A, Romani C, Antognelli C, Andreasen N, Minthon L, Davidsson P, Pottel H, Blennow K, Gallai V. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. Neurol Sci 2002; 23 (Suppl 2): S95-96.
19. Sobow T, Flirski M, Liberski PP. Amyloid-beta and tau proteins as biochemical markers of Alzheimer's disease. Acta Neurobiol Exp (Wars) 2004; 64: 53-70.
20. Sobow T, Flirski M, Kloszewska I, Liberski PP. Plasma levels of Aβ peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. Acta Neurobiol Exp (Wars) 2005; 65: 117-124.
21. Shaw KT, Utsuki T, Rogers J, Yu QS, Sambamurti K, Brossi A, Ge YW, Lahiri DK, Greig NH. Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci USA 2001; 98: 7605-7610.
22. Yan Z, Feng J. Alzheimer's disease: interactions between cholinergic functions and beta-amyloid. Curr Alzheimer Res 2004; 1: 241-248.
23. Zimmermann M, Borroni B, Cattabeni F, Padovani A, Di Luca M. Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients. Neurobiol Dis 2005; 19: 237-242.